|
Delayed
Hong Kong S.E.
11:08:29 17/08/2026 +03
|
5-day change | 1st Jan Change | ||
| 1.080 HKD | +3.85% |
|
+1.89% | +35.00% |
| 08-03 | Fusen Pharmaceutical Company Limited Selected in National Centralised Medicines Procurement in China | CI |
| 06-26 | Fusen Pharma Gets Marketing Nod for Influenza Drug in China | MT |
Company Valuation: Fusen Pharmaceutical Company Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 2,952 | 768.5 | 959.1 | 926.5 | 555.8 | 531.5 |
| Change | - | -73.96% | 24.8% | -3.4% | -40.01% | -4.37% |
| Enterprise Value (EV) 1 | 2,838 | 927.5 | 1,059 | 1,240 | 923 | 753.5 |
| Change | - | -67.32% | 14.22% | 17.09% | -25.59% | -18.37% |
| P/E | 42.9x | 50.5x | -25.3x | -24.9x | -2.95x | -45.1x |
| PBR | 4.48x | 1.17x | 1.56x | 1.64x | 1.5x | 1.48x |
| PEG | - | -0.7x | 0x | - | -0x | 0.5x |
| Capitalization / Revenue | 6.06x | 1.99x | 1.95x | 1.64x | 1.7x | 1.94x |
| EV / Revenue | 5.83x | 2.4x | 2.15x | 2.19x | 2.83x | 2.76x |
| EV / EBITDA | 29x | 11.1x | 14.6x | 25x | -28.4x | 32.3x |
| EV / EBIT | 34.8x | 14.1x | 23.3x | 57.8x | -13.7x | -82.6x |
| EV / FCF | 23.6x | -5.37x | 7.02x | -7.8x | 20x | 6.93x |
| FCF Yield | 4.24% | -18.6% | 14.2% | -12.8% | 5% | 14.4% |
| Dividend per Share 2 | 0.0091 | 0.0091 | - | - | - | - |
| Rate of return | 0.24% | 0.9% | - | - | - | - |
| EPS 2 | 0.0892 | 0.02 | -0.05 | -0.05 | -0.2551 | -0.0159 |
| Distribution rate | 10.2% | 45.5% | - | - | - | - |
| Net sales 1 | 486.9 | 385.7 | 491.8 | 565.6 | 326 | 273.4 |
| EBITDA 1 | 97.96 | 83.35 | 72.33 | 49.56 | -32.5 | 23.32 |
| EBIT 1 | 81.55 | 65.92 | 45.41 | 21.45 | -67.18 | -9.122 |
| Net income 1 | 70.13 | 16.64 | -34.6 | -36.28 | -188.8 | -11.78 |
| Net Debt 1 | -114 | 159 | 100.3 | 313.9 | 367.2 | 222 |
| Reference price 2 | 3.8313 | 1.0102 | 1.2649 | 1.2436 | 0.7518 | 0.7189 |
| Nbr of stocks (in thousands) | 770,434 | 760,744 | 758,210 | 745,034 | 739,301 | 739,301 |
| Announcement Date | 4/23/21 A | 4/28/22 A | 4/28/23 A | 4/26/24 A | 4/30/25 A | 4/30/26 A |
1CNY in Million2CNY
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 97.98M | |
| 35.61x | 6.69x | 23.16x | 0.89% | 48.43B | |
| 18.56x | 2.2x | 10x | 1.37% | 39.72B | |
| 28.23x | 3.44x | 17.81x | 0.9% | 12.25B | |
| 27.22x | 3.89x | 16.12x | 0.59% | 11.84B | |
| 18.63x | 3.31x | 11.51x | 3.87% | 9.06B | |
| 9.11x | 2.11x | 5.48x | 4.42% | 7.57B | |
| 15.83x | 2.06x | 6.7x | 3.22% | 7.18B | |
| 35.19x | 4.02x | 17.09x | 0.23% | 6.84B | |
| Average | 23.55x | 3.46x | 13.48x | 1.94% | 15.89B | |
| Weighted average by Cap. | 26.05x | 4.11x | 15.67x | 1.46% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 1652 Stock
- Valuation Fusen Pharmaceutical Company Limited
Select your edition
All financial news and data tailored to specific country editions
